Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586-597.
Cherry JD. Parvovirus infections in children and adults. Adv Pediatr. 1999;46:245-69.
American Academy of Pediatrics. Parvovirus B19 (Erythema Infectiosum, fifth disease). 30th ed. In: Kimberlin DW, Brady MT, Jackson MA, et al. eds. Red book: 2015 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:593-596.
1. Hashimoto H, Yuno T. Parvovirus B19-associated purpuric-petechial eruption. J Clin Virol. 2011;52:269-271.
2. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586-597.
3. Shimohata H, Higuchi T, Ogawa Y, et al. Human parvovirus B19-induced acute glomerulonephritis: a case report. Ren Fail. 2013;35:159-162.
4. Huang RJ, Varr BC, Triadafilopoulos G. Acute fulminant hepatic failure associated with parvovirus B19 infection in an immunocompetent adult. Dig Dis Sci. 2012;57:2811-2813.
5. Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis. 2009;48:1713-1723.
6. Barah F, Whiteside S, Batista S, et al. Neurological aspects of human parvovirus B19 infection: a systematic review. Rev Med Virol. 2014;24:154-168.
7. Molina KM, Garcia X, Denfield SW, et al. Parvovirus B19 myocarditis causes significant morbidity and mortality in children. Pediatr Cardiol. 2013;34:390-397.
8. Cherry JD. Parvovirus infections in children and adults. Adv Pediatr. 1999;46:245-69.
9. Azzi A, Morfini M, Mannucci PM. The transfusion associated transmission of Parvovirus B19. Transfus Med Rev. 1999;13:194-204.
10. Yu MY, Alter HJ, Virata-Theimer ML, et al. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion. 2010;50:1712-1721.
12. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330:1192-1196.
13. Anand A, Gray ES, Brown T, et al. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987;316:183-186.
14. American Academy of Pediatrics. Parvovirus B19 (Erythema Infectiosum, fifth disease). 30th ed. In: Kimberlin DW, Brady MT, Jackson MA, et al. eds. Red book: 2015 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:593-596.
15. Bernstein DI, Sahly HM, Keitel WA, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011;29:7357-7363.
16. Bansal GP, Hatfield JA, Dunn FE, et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis. 1993;167;1034-1044.
17. Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis. 2003;187;675-678.
18. Chandramouli S, Medina-Selby A, Coit D, et al. Generation of a parvovirus B19 vaccine candidate. Vaccine. 2013;31:3872-3878.
19. Koch WC, Harger JH, Barnstein B, et al. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J. 1998;17:489-494.
20. Rosa C. Rubella and rubeola. Semin Perinatol. 1998;22:318-322.
21. Centers for Disease Control and Prevention. Specimens for detection of measles RNA by RT–PCR or virus isolation. July 2017 [internet publication].
22. Stoeckle MY. The spectrum of human herpesvirus 6 infection: from roseola infantum to adult disease. Annu Rev Med. 2000;51:423-430.
23. Manders S. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol. 1998;39:383-398.
24. Bratton RL, Nesse RE. St Anthony's Fire: diagnosis and management of erysipelas. Am Fam Physician. 1995;51:401-404.
25. Crabol Y, Terrier B, Rozenberg F, et al; Groupe d'experts de l'Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56:968-977.
26. Miller E, Fairley CK, Cohen BJ, et al. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol. 1998;105:174-178.
27. Gratacos E, Torres PJ, Vidal J, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis. 1995;171:1360-1363.
28. Fairley CK, Smoleniec JS, Caul OE, et al. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19. Lancet. 1995;346:1335-1337.
29. Selbing A, Jesefsson A, Dahlo LO, et al. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet. 1995;345:660-661.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台